Ocumetics Expertise Corp. (TSXV:OTC, OTCQB:OTCFF, FRA:2QBO) focuses on a groundbreaking imaginative and prescient enhancement product – the Ocumetics Accommodating Lens. Main the forefront of analysis and product growth, Ocumetic’s intraocular lens (IOL) is engineered to seamlessly shift the attention’s focus from near far distances with none noticeable lag. This course of is named lodging.
The attention’s pure lens loses its flexibility to bend mild rays precisely as a result of getting older and accidents. This results in the deterioration of eyesight and potential situations like cataracts with or with out astigmatism. Ocumetics has designed a really distinctive IOL that’s surgically implanted to revive a affected person’s imaginative and prescient. This lens is designed to harmoniously align with the attention’s pure mechanisms, enhancing imaginative and prescient by appropriately bending mild rays. Notably, it is designed to final a lifetime, presenting a major potential development over different cataract applied sciences.
Ocumetics goals to unravel the issue of eyesight degradation. The proposed resolution is a surgically implanted lens that takes over the perform of correctly bending rays of sunshine by working with the attention’s pure mechanisms, leading to enhanced imaginative and prescient. Following a collection of product enhancements, growth of surgical process protocols, and animal testing for biocompatibility, the Ocumetics Accommodating Lens will quickly start human trials as the corporate works towards bringing the product to market.
- Ocumetics Expertise Corp. is an R&D firm creating a imaginative and prescient enhancement product with the potential to disrupt the imaginative and prescient correction trade.
- The Ocumetics Accommodating Lens is an intraocular lens designed to permit the human eye to shift between shut and long-distance photographs with out perceptible adjustment lag.
- Ocumetics’ product is surgically implanted and is designed to boost the pure processes, permitting the affected person’s eyes to bend mild correctly for higher imaginative and prescient.
- The Ocumetics Accommodating Lens has considerably accomplished a collection of design enhancements, animal research, surgical process growth and biocompatibility research and can quickly transfer towards human scientific trials, slated to start in Q1 2024.
- The corporate goals to obtain full US FDA approval inside three-and-a-half years and convey its product to a projected intraocular lens market phase of US$6.4 billion by 2030 (Delveinsight 2022).
- An skilled staff with expertise in scientific eye care, R&D and company growth is main the corporate towards bringing its transformative product to market.
This Ocumetics Expertise profile is a part of a paid investor training marketing campaign.*